718 related articles for article (PubMed ID: 16010093)
1. The significance of ferritin, lipid-associated sialic acid, CEA, squamous cell carcinoma (SCC) antigen, and CYFRA 21-1 levels in SCC of the head and neck.
Inal E; Laçin M; Asal K; Ceylan A; Köybaşioğlu A; Ileri F; Uslu SS
Kulak Burun Bogaz Ihtis Derg; 2004; 12(1-2):23-30. PubMed ID: 16010093
[TBL] [Abstract][Full Text] [Related]
2. CYFRA 21-1 is not superior to SCC antigen and CEA in head and neck squamous cell cancer.
Wollenberg B; Jan V; Schmit UM; Hofmann K; Stieber P; Fateh-Moghadam A
Anticancer Res; 1996; 16(5B):3117-24. PubMed ID: 8920778
[TBL] [Abstract][Full Text] [Related]
3. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P
J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
[TBL] [Abstract][Full Text] [Related]
4. CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA.
Molina R; Filella X; Augé JM; Bosch E; Torne A; Pahisa J; Lejarcegui JA; Rovirosa A; Mellado B; Ordi J; Biete A
Anticancer Res; 2005; 25(3A):1765-71. PubMed ID: 16033097
[TBL] [Abstract][Full Text] [Related]
5. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
6. CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma.
Yamamoto K; Oka M; Hayashi H; Tangoku A; Gondo T; Suzuki T
Cancer; 1997 May; 79(9):1647-55. PubMed ID: 9128978
[TBL] [Abstract][Full Text] [Related]
7. Clinical effectiveness of tumor markers in squamous cell carcinoma of the larynx.
Eleftheriadou A; Chalastras T; Ferekidou E; Kyriou L; Yiotakis I; Pappas Z; Ferekidis E; Kandiloros D
Anticancer Res; 2006; 26(3B):2493-7. PubMed ID: 16821638
[TBL] [Abstract][Full Text] [Related]
8. Combined use of established and novel tumour markers in the diagnosis of head and neck squamous cell carcinoma.
Ayude D; Gacio G; Páez de la Cadena M; Pallas E; Martínez-Zorzano VS; de Carlos A; Rodríguez-Berrocal FJ
Oncol Rep; 2003; 10(5):1345-50. PubMed ID: 12883705
[TBL] [Abstract][Full Text] [Related]
9. Tumor markers and lymphatic metastasis in head and neck cancer patients.
Büntzel J; Hornig A; Glatzel M; Micke O; Bruns F; Schäfer U; Fröhlich D
Anticancer Res; 2005; 25(3A):1539-42. PubMed ID: 16033056
[TBL] [Abstract][Full Text] [Related]
10. Cytokeratin subunit 19 measured by CYFRA 21-1 assay in follow-up of cervical cancer.
Kainz C; Sliutz G; Mustafa G; Bieglmayr C; Koelbl H; Reinthaller A; Gitsch G
Gynecol Oncol; 1995 Mar; 56(3):402-5. PubMed ID: 7535720
[TBL] [Abstract][Full Text] [Related]
11. [Diagnosis of recurrences of head and neck carcinoma with the tumor marker SSC-antigen].
Arlt A; Luckhaupt H; Hildmann H
Laryngorhinootologie; 2000 Apr; 79(4):207-12. PubMed ID: 10838684
[TBL] [Abstract][Full Text] [Related]
12. [Study of Cyfra 21-1 as a new tumor marker for the diagnosis of epidermoid carcinoma of the head and neck].
González Sánchez E; López-Ríos Velasco J; Calvo Boizas E; García-Talavera Fernández JR; Martín Ro-dríguez M; Muñoz Herrera A; Del Cañizo Alvarez A
Acta Otorrinolaringol Esp; 1999 Mar; 50(2):85-9. PubMed ID: 10217679
[TBL] [Abstract][Full Text] [Related]
13. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
[TBL] [Abstract][Full Text] [Related]
14. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
[TBL] [Abstract][Full Text] [Related]
15. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of osteopontin in esophageal squamous cell carcinoma: comparison with common tumor markers.
Shimada Y; Watanabe G; Kawamura J; Soma T; Okabe M; Ito T; Inoue H; Kondo M; Mori Y; Tanaka E; Imamura M
Oncology; 2005; 68(2-3):285-92. PubMed ID: 16015046
[TBL] [Abstract][Full Text] [Related]
17. Clinical usefulness of CYFRA 21-1 for esophageal squamous cell carcinoma in radiation therapy.
Wakatsuki M; Suzuki Y; Nakamoto S; Ohno T; Ishikawa H; Kiyohara H; Kiyozuka M; Shirai K; Nakayama Y; Nakano T
J Gastroenterol Hepatol; 2007 May; 22(5):715-9. PubMed ID: 17444861
[TBL] [Abstract][Full Text] [Related]
18. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
[TBL] [Abstract][Full Text] [Related]
19. Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21-1 and TPS in oral squamous cell carcinoma.
Nagler RM; Barak M; Peled M; Ben-Aryeh H; Filatov M; Laufer D
Cancer; 1999 Mar; 85(5):1018-25. PubMed ID: 10091783
[TBL] [Abstract][Full Text] [Related]
20. Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma.
Deng YF; Chen P; Lin YZ; Le JZ; Wu XL; Yu MQ; Zhuang PY; Gao MH
J Laryngol Otol; 2003 Mar; 117(3):190-4. PubMed ID: 12648374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]